<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2enclosuresfull.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:tho="http://www.theheart.org/rss/tho-ext-1.0.xsd" xmlns:media="http://search.yahoo.com/mrss/" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">
  <channel>
    <title>The Bob Harrington Show - Interventional cardiology news</title>
    <link>http://radio.theheart.org/bob-harrington-show</link>
    <description>Podcasts about interventional cardiology news with Dr Robert A. Harrington from Duke Clinical Research Institute.</description>
    <itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle>
    <language>en-us</language>
    <itunes:author>theheart.org</itunes:author>
    <itunes:owner>
      <itunes:name>theheart.org</itunes:name>
      <itunes:email>info@theheart.org</itunes:email>
    </itunes:owner>
    <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/itunes_art_url.jpg" />
    <image>
      <url>http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg</url>
      <description>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</description>
      <link>http://radio.theheart.org/bob-harrington-show</link>
    </image>
    <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://feeds.feedburner.com/bob-harrington-show" /><feedburner:info uri="bob-harrington-show" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><media:thumbnail url="http://radio.theheart.org/images/bob-harrington-show/itunes_art_url.jpg" /><itunes:explicit>no</itunes:explicit><item>
      <title>#47: Rebooting the medical system with Dr Eric Topol </title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Technology is the key to a radical transformation of medicine, which is shifting from a population-based model to one of individualization. Will cardiologists and medical practitioners be left behind?&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=yzjv4FWvDZ8:_TYcmqky3j8:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=yzjv4FWvDZ8:_TYcmqky3j8:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=yzjv4FWvDZ8:_TYcmqky3j8:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=yzjv4FWvDZ8:_TYcmqky3j8:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=yzjv4FWvDZ8:_TYcmqky3j8:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=yzjv4FWvDZ8:_TYcmqky3j8:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=yzjv4FWvDZ8:_TYcmqky3j8:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=yzjv4FWvDZ8:_TYcmqky3j8:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=yzjv4FWvDZ8:_TYcmqky3j8:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=yzjv4FWvDZ8:_TYcmqky3j8:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=yzjv4FWvDZ8:_TYcmqky3j8:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=yzjv4FWvDZ8:_TYcmqky3j8:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=yzjv4FWvDZ8:_TYcmqky3j8:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=yzjv4FWvDZ8:_TYcmqky3j8:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=yzjv4FWvDZ8:_TYcmqky3j8:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/yzjv4FWvDZ8" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Technology is the key to a radical transformation of medicine, which is shifting from a population-based model to one of individualization. Will cardiologists and medical practitioners be left behind?]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>Technology is the key to a radical transformation of medicine, which is shifting from a population-based model to one of individualization. Will cardiologists and medical practitioners be left behind? <strong>Dr Eric Topol</strong> discusses his recent book, <em>The Creative Destruction of Medicine</em>, and his thoughts on the future of health and care.</p>
<p>&nbsp;</p>
<p>See also:</p>
<ul>
<li><a href="http://blogs.theheart.org/topolog/2012/1/25/talking-about-a-healthcare-revolution-the-digital-age-ushers-in-precision-medicine">Talking about a (healthcare) revolution: The digital age ushers in precision medicine </a></li>
<li><a href="http://creativedestructionofmedicine.com/">The Creative Destruction of Medicine by Eric Topol</a></li>
</ul>
<p><strong>&nbsp;</strong></p>
<p><strong>Dr Topol </strong>has no relevant financial disclosures.</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/3-1-11%20DCRI%20Director%20COI.pdf">here</a>.</p>]]>
      </tho:content>
      <pubDate>Wed, 11 Apr 2012 15:45:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/yzjv4FWvDZ8/47-rebooting-the-medical-system-with-dr-eric-topol</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2012/4/11/47-rebooting-the-medical-system-with-dr-eric-topol</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2012/4/11/47-rebooting-the-medical-system-with-dr-eric-topol#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="47-rebooting-the-medical-system-with-dr-eric-topol" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/47-rebooting-the-medical-system-with-dr-eric-topol.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/hRCxAGKvCuU/Harrington_Show_Apr11.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2012/4/11/47-rebooting-the-medical-system-with-dr-eric-topol</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/hRCxAGKvCuU/Harrington_Show_Apr11.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode47/Harrington_Show_Apr11.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#46: Healthcare reform and cardiovascular practice in the election year with Dr Kevin Schulman </title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Where do things stand with healthcare reform? What is the status of CMS innovation centers, accountable care models (ACOs), and new models for reimbursement?&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=d65y8pUapS8:Bo3kCtqu2hk:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=d65y8pUapS8:Bo3kCtqu2hk:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=d65y8pUapS8:Bo3kCtqu2hk:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=d65y8pUapS8:Bo3kCtqu2hk:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=d65y8pUapS8:Bo3kCtqu2hk:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=d65y8pUapS8:Bo3kCtqu2hk:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=d65y8pUapS8:Bo3kCtqu2hk:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=d65y8pUapS8:Bo3kCtqu2hk:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=d65y8pUapS8:Bo3kCtqu2hk:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=d65y8pUapS8:Bo3kCtqu2hk:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=d65y8pUapS8:Bo3kCtqu2hk:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=d65y8pUapS8:Bo3kCtqu2hk:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=d65y8pUapS8:Bo3kCtqu2hk:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=d65y8pUapS8:Bo3kCtqu2hk:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=d65y8pUapS8:Bo3kCtqu2hk:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/d65y8pUapS8" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Where do things stand with healthcare reform? What is the status of CMS innovation centers, accountable care models (ACOs), and new models for reimbursement? ]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>Where do things stand with healthcare reform?<strong> </strong>What is the status of CMS innovation centers, accountable care models (ACOs), and new models for reimbursement? <strong>Dr Kevin Schulman,</strong> professor of medicine and business administration, joins the show to discuss healthcare reform and its implications on cardiology&mdash;and society at-large&mdash;in 2012. What are the implications of the trend toward hospital employment vs private practice? Does it make a difference whom we vote for? Beyond the election, what can medical schools do to prepare physicians for the reality of practice in increasingly difficult financial circumstances?<strong>&nbsp;</strong></p>
<p>See also:</p>
<ul>
<li><a href="../../../2011/3/30/34-healthcare-reform-update-clinical-and-business-implications-for-cardiologists">#34: Healthcare reform update: Clinical and business implications for cardiologists </a></li>
<li><a href="../../../2010/4/26/episode-22-business-and-practice-implications-of-healthcare-reform-with-physician-and">#22: Business and practice implications of healthcare reform with physician and business school leader Dr Kevin Schulman</a></li>
<li><a title="What is the way forward for private practice in the US? Drs Bilazarian, Skolnick, and Walton-Shirley debate the options." href="http://theheart.org/editorial-program/1156159.do">Hospital bound? Private-practice cardiology in uncertain times&nbsp;</a></li>
</ul>
<p>&nbsp;</p>
<p><strong>Dr Schulman </strong>has no relevant financial disclosures.</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/3-1-11%20DCRI%20Director%20COI.pdf">here</a>.</p>]]>
      </tho:content>
      <pubDate>Thu, 15 Mar 2012 16:30:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/d65y8pUapS8/46-healthcare-reform-and-cardiovascular-practice-in-the-election-year-with-dr-kevin-schulman</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2012/3/14/46-healthcare-reform-and-cardiovascular-practice-in-the-election-year-with-dr-kevin-schulman</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2012/3/14/46-healthcare-reform-and-cardiovascular-practice-in-the-election-year-with-dr-kevin-schulman#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="46-healthcare-reform-and-cardiovascular-practice-in-the-election-year-with-dr-kevin-schulman" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/46-healthcare-reform-and-cardiovascular-practice-in-the-election-year-with-dr-kevin-schulman.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/nGxHgMDpkGc/Harrington_Show_mar15.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2012/3/14/46-healthcare-reform-and-cardiovascular-practice-in-the-election-year-with-dr-kevin-schulman</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/nGxHgMDpkGc/Harrington_Show_mar15.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode46/Harrington_Show_mar15.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#45: Clopidogrel pharmacogenomics: Challenges, controversies, and clinical implications with Dr Jessica Mega</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Clopidogrel pharmacogenomics: Challenges, controversies, and clinical implications with Dr Jessica Mega&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=OtXL0N1JYEQ:xK0ta96cZvo:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=OtXL0N1JYEQ:xK0ta96cZvo:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=OtXL0N1JYEQ:xK0ta96cZvo:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=OtXL0N1JYEQ:xK0ta96cZvo:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=OtXL0N1JYEQ:xK0ta96cZvo:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=OtXL0N1JYEQ:xK0ta96cZvo:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=OtXL0N1JYEQ:xK0ta96cZvo:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=OtXL0N1JYEQ:xK0ta96cZvo:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=OtXL0N1JYEQ:xK0ta96cZvo:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=OtXL0N1JYEQ:xK0ta96cZvo:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=OtXL0N1JYEQ:xK0ta96cZvo:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=OtXL0N1JYEQ:xK0ta96cZvo:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=OtXL0N1JYEQ:xK0ta96cZvo:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=OtXL0N1JYEQ:xK0ta96cZvo:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=OtXL0N1JYEQ:xK0ta96cZvo:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/OtXL0N1JYEQ" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Clopidogrel pharmacogenomics: Challenges, controversies, and clinical implications with Dr Jessica Mega]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>The issue of clopidogrel genomics and <em>CYP2C19</em> genotyping came to a head with the recent <a href="http://jama.ama-assn.org/content/306/24/2704.short?rss=1"><em>JAMA</em> meta-analysis</a> that questioned the use of clopidogrel loss-of-function gene testing&mdash;controversially stating that there is no link between genotype and cardiovascular events. <strong>Dr Jessica Mega </strong>joins the show to shine light on the rapidly evolving field of clopidogrel pharmacogenomics, examine the scientific data&mdash;and the controversy&mdash;and share her recommendations for practitioners.</p>
<p>See also:</p>
<p>Holmes MV, Perel P, Shah T, et al. <em>CYP2C19</em> genotype, clopidogrel metabolism, platelet function, and cardiovascular events. <em>JAMA</em> 2011; 306:2704-2714. Available <a href="http://jama.ama-assn.org/content/306/24/2704.short?rss=1">here</a>.</p>
<p><a title="A new meta-analysis and especially an accompanying editorial argue against current use of CYP2C19 genotyping to define risk of subsequent CV events in patients considered for clopidogrel. Proponents of the test defend its use and describe what they see as" href="http://www.theheart.org/article/1334629.do">Analysis slams use of clopidogrel loss-of-function gene test; proponents fire back </a><strong></strong></p>
<p><a href="http://blogs.theheart.org/topolog/2011/12/27/miscue-in-clopidogrel-pharmacogenomics">An important miscue in clopidogrel pharmacogenomics</a></p>
<p><a title="UPDATED / / Tripling the maintenance dose of clopidogrel to 225 mg daily in stable heart disease patients carrying one clopidogrel loss-of-function allele achieved levels of platelet reactivity, but in patients homozygous for the CYP2C19*2 allele, even 30" href="http://theheart.org/article/1312759.do">ELEVATE-TIMI 56: Clopidogrel 225 mg for patients with one loss-of-function allele </a><strong></strong></p>
<p><a title="This argues against the recommendation in the boxed warning on the clopidogrel label about poor metabolizers, which suggests clopidogrel 150 mg as a potential option for these patients." href="http://theheart.org/article/1208199.do">GRAVITAS gene study: <em>CYP2C19</em>*2 carriers do not respond to high-dose clopidogrel </a></p>
<p><strong>Dr Mega</strong> has served as an advisor or consultant for AstraZeneca, Bristol-Myers Squibb, Gilead, Merck, and Sanofi-Aventis. She has received grants for clinical research from Accumetrics, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Johnson &amp; Johnson, Nanosphere, Sanofi-Aventis, and Eli Lilly.</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/3-1-11%20DCRI%20Director%20COI.pdf">here</a>.</p>]]>
      </tho:content>
      <pubDate>Fri, 10 Feb 2012 14:35:00 -0500</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/OtXL0N1JYEQ/45-clopidogrel-pharmacogenomics-challenges-controversies-and-clinical-implications-with-dr-jessica-mega</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2012/2/9/45-clopidogrel-pharmacogenomics-challenges-controversies-and-clinical-implications-with-dr-jessica-mega</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2012/2/9/45-clopidogrel-pharmacogenomics-challenges-controversies-and-clinical-implications-with-dr-jessica-mega#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="45-clopidogrel-pharmacogenomics-challenges-controversies-and-clinical-implications-with-dr-jessica-mega" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/45-clopidogrel-pharmacogenomics-challenges-controversies-and-clinical-implications-with-dr-jessica-mega.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>1</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/K5rTBTNXoVk/Harrington_Show_Feb10.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2012/2/9/45-clopidogrel-pharmacogenomics-challenges-controversies-and-clinical-implications-with-dr-jessica-mega</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/K5rTBTNXoVk/Harrington_Show_Feb10.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode45/Harrington_Show_Feb10.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#44:  Improving patient adherence to medication with Dr Eric Peterson  </title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Patient adherence to medication has long defied quantification, with many physicians assuming that the cost of medications is the primary factor explaining poor rates of compliance. How do we explain abysmal rates of patient adherence to medication?&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=1qg1GOUqhQU:P1CWIEuBoHY:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=1qg1GOUqhQU:P1CWIEuBoHY:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=1qg1GOUqhQU:P1CWIEuBoHY:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=1qg1GOUqhQU:P1CWIEuBoHY:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=1qg1GOUqhQU:P1CWIEuBoHY:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=1qg1GOUqhQU:P1CWIEuBoHY:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=1qg1GOUqhQU:P1CWIEuBoHY:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=1qg1GOUqhQU:P1CWIEuBoHY:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=1qg1GOUqhQU:P1CWIEuBoHY:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=1qg1GOUqhQU:P1CWIEuBoHY:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=1qg1GOUqhQU:P1CWIEuBoHY:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=1qg1GOUqhQU:P1CWIEuBoHY:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=1qg1GOUqhQU:P1CWIEuBoHY:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=1qg1GOUqhQU:P1CWIEuBoHY:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=1qg1GOUqhQU:P1CWIEuBoHY:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/1qg1GOUqhQU" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Patient adherence to medication has long defied quantification, with many physicians assuming that the cost of medications is the primary factor explaining poor rates of compliance. How do we explain abysmal rates of patient adherence to medication? ]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>Patient adherence to medication has long defied quantification, with many physicians assuming that the cost of medications is the primary factor explaining poor rates of compliance. The <strong>MI </strong><a href="http://www.theheart.org/article/1310073.do"><strong>FREEE </strong>trial</a> conducted by <strong>Dr Niteesh Choudry, </strong>and presented during <strong>AHA 2011</strong> offers stunning proof that compliance is a more complicated issue than cost alone and raises numerous issues that our guest <strong>Dr Eric Peterson</strong> discusses. How do we explain abysmal rates of patient adherence to medication? Should the physician be held responsible for adherence?</p>
<p>See:</p>
<p><a href="http://www.theheart.org/article/1310073.do">Cutting copays for post-MI drugs helps outcomes, with no added cost to insurers</a></p>
<p>Choudhry N, Avorn J, Glynn R, et al. The impact of full coverage for preventative medications after myocardial infarction on recurrent vascular events and health spending: The post-myocardial infarction free Rx event and economic evaluation (MI FREEE) trial. <em>N Engl J Med </em>2011; DOI: 10.1056/NEJMsa110793. Available at: <a href="http://www.theheart.org/viewDocument.do?document=http%3A%2F%2Fwww.nejm.org" target="_blank">http://www.nejm.org</a></p>
<p>Aetna. Aetna launching value-based program that improves medication adherence, cost and outcomes for members who have suffered from heart attacks [press release]. November 14, 2011. Available <a href="http://www.theheart.org/viewDocument.do?document=http%3A%2F%2Fwww.aetna.com%2Fnews%2FnewsReleases%2F2011%2F1114-AetnaRx-HealthyOutcomes.html" target="_blank">here</a>.</p>
<p>Goldman L and Epstein AM. Improving adherence&mdash;money isn't the only thing. <em>N Engl J Med </em>2011; DOI:10.1056/nejme1111558. Available at: <a href="http://www.theheart.org/viewDocument.do?document=http%3A%2F%2Fwww.nejm.org" target="_blank">http://www.nejm.org</a>.</p>
<p><strong>Dr Peterson</strong> has received grants for clinical research from Bristol-Myers Squibb, Eli Lilly, Johnson &amp; Johnson, and Sanofi-Aventis</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/3-1-11%20DCRI%20Director%20COI.pdf">here</a>.</p>]]>
      </tho:content>
      <pubDate>Mon, 09 Jan 2012 15:45:00 -0500</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/1qg1GOUqhQU/44--improving-patient-adherence-to-medication-with-dr-eric-peterson</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2012/1/9/44--improving-patient-adherence-to-medication-with-dr-eric-peterson</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2012/1/9/44--improving-patient-adherence-to-medication-with-dr-eric-peterson#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="44--improving-patient-adherence-to-medication-with-dr-eric-peterson" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/44--improving-patient-adherence-to-medication-with-dr-eric-peterson.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>1</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/7QNgtKQYeOQ/Harrington_Show_Jan9.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2012/1/9/44--improving-patient-adherence-to-medication-with-dr-eric-peterson</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/7QNgtKQYeOQ/Harrington_Show_Jan9.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode44/Harrington_Show_Jan9.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#43: Same-day discharge from the hospital after elective PCI with Dr Sunil Rao</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>What is the best way to care for patients following PCI? Is same-day discharge a viable—or even desirable—option? Dr Sunil Rao joins the show to discuss his recent paper in JAMA, including the background for the study, source of data, and methodology.&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=z2A4lZiJBJk:ehM4MyEQor8:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=z2A4lZiJBJk:ehM4MyEQor8:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=z2A4lZiJBJk:ehM4MyEQor8:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=z2A4lZiJBJk:ehM4MyEQor8:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=z2A4lZiJBJk:ehM4MyEQor8:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=z2A4lZiJBJk:ehM4MyEQor8:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=z2A4lZiJBJk:ehM4MyEQor8:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=z2A4lZiJBJk:ehM4MyEQor8:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=z2A4lZiJBJk:ehM4MyEQor8:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=z2A4lZiJBJk:ehM4MyEQor8:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=z2A4lZiJBJk:ehM4MyEQor8:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=z2A4lZiJBJk:ehM4MyEQor8:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=z2A4lZiJBJk:ehM4MyEQor8:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=z2A4lZiJBJk:ehM4MyEQor8:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=z2A4lZiJBJk:ehM4MyEQor8:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/z2A4lZiJBJk" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[What is the best way to care for patients following PCI? Is same-day discharge a viable—or even desirable—option? Dr Sunil Rao joins the show to discuss his recent paper in JAMA, including the background for the study, source of data, and methodology.]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>What is the best way to care for patients following PCI? Is same-day discharge a viable&mdash;or even desirable&mdash;option? <strong>Dr Sunil Rao</strong> joins the show to discuss his <a href="http://jama.ama-assn.org/content/306/13/1461">recent paper in <em>JAMA</em></a>, including the background for the study, source of data, and methodology. Discussion focuses on the thorny issues of cost savings and policy implications as well as technical issues to consider when evaluating whether to discharge a patient (or not).</p>
<p>See:</p>
<p><a title="Among selected Medicare patients, same-day discharge is still uncommon, but investigators observed nearly equivalent rates of death and hospitalization at 30 days when compared with patients who stayed overnight." href="http://www.theheart.org/article/1290247.do">Same-day discharge after elective PCI as safe as overnight stays </a></p>
<p>Rao SV, Kaltenbach LA, Weintraub WS, et al. Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older adults. <em>JAMA</em> 2011; 306:1461-1467. <a href="http://jama.ama-assn.org/content/306/13/1461">Abstract</a>.</p>
<p>Dr Rao has served as an advisor or consultant for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Sanofi-Aventis, and the Medicines Company. He has served as a speaker or a member of a speaker's bureau for Bristol-Myers Squibb, Sanofi-Aventis, Terumo, and the Medicines Company. Dr Rao has received grants for clinical research from Cordis, Ikaria, and Sanofi-Aventis.</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/Harrington-COI_2010.pdf">here</a>.</p>]]>
      </tho:content>
      <pubDate>Wed, 07 Dec 2011 14:30:00 -0500</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/z2A4lZiJBJk/43-sameday-discharge-from-the-hospital-after-elective-pci</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2011/12/7/43-sameday-discharge-from-the-hospital-after-elective-pci</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2011/12/7/43-sameday-discharge-from-the-hospital-after-elective-pci#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="43-sameday-discharge-from-the-hospital-after-elective-pci" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/43-sameday-discharge-from-the-hospital-after-elective-pci.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/jUnOxZswD4g/Harrington_Show_Dec7.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2011/12/7/43-sameday-discharge-from-the-hospital-after-elective-pci</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/jUnOxZswD4g/Harrington_Show_Dec7.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode43/Harrington_Show_Dec7.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#42: Statins--Cardiovascular benefit vs diabetes risk with Dr Michael Cobble</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Statins have become a cornerstone therapy in the prevention of cardiovascular disease by helping to modify the risk profile of millions of people. But what about a possible connection between statin use and diabetes?&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=aKCqd1VqiX0:-rUT9bye5XI:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=aKCqd1VqiX0:-rUT9bye5XI:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=aKCqd1VqiX0:-rUT9bye5XI:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=aKCqd1VqiX0:-rUT9bye5XI:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=aKCqd1VqiX0:-rUT9bye5XI:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=aKCqd1VqiX0:-rUT9bye5XI:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=aKCqd1VqiX0:-rUT9bye5XI:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=aKCqd1VqiX0:-rUT9bye5XI:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=aKCqd1VqiX0:-rUT9bye5XI:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=aKCqd1VqiX0:-rUT9bye5XI:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=aKCqd1VqiX0:-rUT9bye5XI:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=aKCqd1VqiX0:-rUT9bye5XI:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=aKCqd1VqiX0:-rUT9bye5XI:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=aKCqd1VqiX0:-rUT9bye5XI:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=aKCqd1VqiX0:-rUT9bye5XI:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/aKCqd1VqiX0" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Statins have become a cornerstone therapy in the prevention of cardiovascular disease by helping to modify the risk profile of millions of people. But what about a possible connection between statin use and diabetes? ]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>Statins have become a cornerstone therapy in the prevention of cardiovascular disease by helping to modify the risk profile of millions of people. But what about a possible connection between statin use and diabetes? Lipidologist and preventive expert <strong>Dr Michael Cobble</strong> joins the show to relate his examination of the data and clinical experience and share his thoughts on the advantages of statin use relative to the risk of diabetes.</p>
<p>See:</p>
<p><a href="http://theheart.org/article/1279205.do">Should you start a statin in a newly diagnosed diabetic?</a></p>
<p>Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statins trials. <em>Lancet</em> 2010; 375:735-742. Available <a href="http://www.thelancet.it/journals/lancet/article/PIIS0140-6736(09)61965-6/abstract">here</a>.</p>
<p>Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. <em>JAMA</em> 2011; 305:2556-2564. Available <a href="http://jama.ama-assn.org/content/305/24/2556">here</a>.</p>
<p><a href="http://www.theheart.org/article/1242233.do" target="_blank">High-dose statin therapy increases the risk of diabetes: Meta-analysis</a></p>
<p><strong>Dr Cobble</strong> has served as an advisor or consultant for Abbott, AstraZeneca, and Bristol Myers-Squibb. He has served as a speaker of member of a speaker's bureau for Abbott, AstraZeneca, Bristol Myers-Squibb, Eli Lilly, Boehringer Ingelheim, Novo, and Forest. Dr Cobble is employed by Atherotech Cardiometabolic Diagnostic Lab and runs a private practice, Canyons Medical Center.</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/Harrington-COI_2010.pdf">here</a>.</p>]]>
      </tho:content>
      <pubDate>Tue, 01 Nov 2011 10:35:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/aKCqd1VqiX0/42-statinscardiovascular-benefit-vs-diabetes-risk</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2011/10/31/42-statinscardiovascular-benefit-vs-diabetes-risk</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2011/10/31/42-statinscardiovascular-benefit-vs-diabetes-risk#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="42-statinscardiovascular-benefit-vs-diabetes-risk" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/42-statinscardiovascular-benefit-vs-diabetes-risk.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>6</tho:commentCount>
      <tho:keywords>EASD 2011 </tho:keywords>
      <itunes:keywords>EASD 2011 </itunes:keywords>
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/iyhvx7vNi8A/Harrington_Show_oct3.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2011/10/31/42-statinscardiovascular-benefit-vs-diabetes-risk</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/iyhvx7vNi8A/Harrington_Show_oct3.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode42/Harrington_Show_oct3.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#41: The ISCHEMIA trial on optimal care for patients with stable coronary disease with Dr...</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>The large ISCHEMIA trial, led by Dr Judith Hochman, seeks to build on the results of COURAGE and BARI 2D to answer the important question: what is the best treatment for patients with stable coronary disease?&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8lddngJ7gsA:aJDT3yt5A6o:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8lddngJ7gsA:aJDT3yt5A6o:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8lddngJ7gsA:aJDT3yt5A6o:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8lddngJ7gsA:aJDT3yt5A6o:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=8lddngJ7gsA:aJDT3yt5A6o:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8lddngJ7gsA:aJDT3yt5A6o:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8lddngJ7gsA:aJDT3yt5A6o:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=8lddngJ7gsA:aJDT3yt5A6o:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8lddngJ7gsA:aJDT3yt5A6o:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8lddngJ7gsA:aJDT3yt5A6o:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=8lddngJ7gsA:aJDT3yt5A6o:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8lddngJ7gsA:aJDT3yt5A6o:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8lddngJ7gsA:aJDT3yt5A6o:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=8lddngJ7gsA:aJDT3yt5A6o:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8lddngJ7gsA:aJDT3yt5A6o:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/8lddngJ7gsA" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[The large ISCHEMIA trial, led by Dr Judith Hochman, seeks to build on the results of COURAGE and BARI 2D to answer the important question: what is the best treatment for patients with stable coronary disease?

]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>Both cardiologists and patients grapple with the concept that fixing a blockage may not prolong life, as indicated by the results of the landmark <a href="http://www.theheart.org/article/779535.do"><strong>COURAGE</strong></a> and <a href="http://www.theheart.org/article/976995.do"><strong>BARI 2D</strong></a> trials and reflected by the limited effect these trials seem to have had on clinical practice.</p>
<p>The large <strong>ISCHEMIA</strong> trial, led by <strong>Dr Judith Hochman</strong>, seeks to build on the results of COURAGE and BARI 2D to answer the important question: what is the best treatment for patients with stable coronary disease?</p>
<p>Dr Hochman joins the show to discuss rationale and trial design and give information on how to become involved in the study.</p>
<p>For more information on ISCHEMIA, click <a href="http://ischemiatrial.org/">here</a>.</p>
<p>To contact the study organizers, click <a href="mailto:ischemia@nyumc.org">here</a>.</p>
<p><strong>Dr Hochman</strong> has no relevant financial disclosures.</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/Harrington-COI_2010.pdf">here</a>.</p>
<p>See also:</p>
<ul>
<li><a title="The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches will compare early coronary intervention with a more conservative approach in about 8000 patients with moderate to severe ischemia." href="http://www.theheart.org/article/1259977.do">Huge ISCHEMIA trial to tackle unanswered COURAGE, BARI 2D questions </a></li>
<li><a title="UPDATED WITH COMMENTARY // Despite the results of the Occluded Artery Trial, as well as the updated 2007 clinical guidelines stating that there is no benefit to intervening late in stable acute-MI patients, physicians continue to treat these patients with" href="http://www.theheart.org/article/1252275.do">Physicians still doing late PCI of occluded arteries in stable patients </a></li>
<li><a href="http://www.theheart.org/editorial-program/1234759.do">European perspectives on appropriate use of PCI </a></li>
<li><a title="UPDATED WITH COMMENTARY // The percentage of patients with stable CAD receiving optimal medical therapy did not noticeably improve following the landmark COURAGE trial in 2007, according to new data from a large PCI registry. The findings have important i" href="http://www.theheart.org/article/1224061.do">New data show COURAGE findings are not being implemented </a></li>
<li><a title="UPDATED WITH COMMENTARY / The two treatment strategies were no different for deaths, MI, stroke, or composite outcomes over a median of 4.6 years, although freedom from angina rates were higher for PCI at earlier time points. Experts stress that PCI still" href="http://www.theheart.org/article/779535.do">Medical therapy takes COURAGE: No benefit of PCI over optimal drugs for preventing events in stable CAD </a></li>
<li><a href="http://www.theheart.org/editorial-program/981221.do">Getting to the bottom of BARI 2D </a></li>
<li><a title="Overall rates of major CV events also were no different between revascularization and medical therapy, although CABG alone&amp;#151;but not PCI&amp;#151;was associated with a reduction in the risk of cardiovascular events, particularly nonfatal MI, compared with " href="http://www.theheart.org/article/976995.do">No mortality, CV-event differences between revascularization and medical therapy in diabetics: BARI 2D </a></li>
</ul>
<p>&nbsp;</p>]]>
      </tho:content>
      <pubDate>Thu, 06 Oct 2011 10:20:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/8lddngJ7gsA/41-the-ischemia-trial-on-optimal-care-for-patients-with-stable-coronary</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2011/10/5/41-the-ischemia-trial-on-optimal-care-for-patients-with-stable-coronary</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2011/10/5/41-the-ischemia-trial-on-optimal-care-for-patients-with-stable-coronary#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="41-the-ischemia-trial-on-optimal-care-for-patients-with-stable-coronary" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/41-the-ischemia-trial-on-optimal-care-for-patients-with-stable-coronary.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/k2fQEhE7dQY/Harrington_Show_Sept22.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2011/10/5/41-the-ischemia-trial-on-optimal-care-for-patients-with-stable-coronary</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/k2fQEhE7dQY/Harrington_Show_Sept22.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode41/Harrington_Show_Sept22.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#40: The civility of professional discourse with Dr Clyde Yancy</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>With the multiplication of methods of communication, the democratization of access to information, and the fast pace of today's technology it's hard not to feel that professional discourse has taken a bashing and that civility in discourse is a lost art.&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=ptts74nMrIE:c8edMANGD2Q:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=ptts74nMrIE:c8edMANGD2Q:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=ptts74nMrIE:c8edMANGD2Q:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=ptts74nMrIE:c8edMANGD2Q:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=ptts74nMrIE:c8edMANGD2Q:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=ptts74nMrIE:c8edMANGD2Q:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=ptts74nMrIE:c8edMANGD2Q:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=ptts74nMrIE:c8edMANGD2Q:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=ptts74nMrIE:c8edMANGD2Q:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=ptts74nMrIE:c8edMANGD2Q:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=ptts74nMrIE:c8edMANGD2Q:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=ptts74nMrIE:c8edMANGD2Q:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=ptts74nMrIE:c8edMANGD2Q:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=ptts74nMrIE:c8edMANGD2Q:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=ptts74nMrIE:c8edMANGD2Q:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/ptts74nMrIE" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[With the multiplication of methods of communication, the democratization of access to information, and the fast pace of today's technology it's hard not to feel that professional discourse has taken a bashing and that civility in discourse is a lost art.]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>With the multiplication of methods of communication, the democratization of access to information, and the fast pace of today's technology it's hard not to feel that professional discourse has taken a bashing and that civility in discourse is a lost art. <strong>Dr Clyde Yancy</strong> joins the show to talk about manners, anonymity, and broader societal issues that contribute to professional discourse and why it's important to remain optimistic.<strong></strong></p>
<p><strong>Dr Yancy </strong>has no relevant financial disclosures.</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/Harrington-COI_2010.pdf">here</a>.</p>]]>
      </tho:content>
      <pubDate>Mon, 12 Sep 2011 14:15:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/ptts74nMrIE/40-the-civility-of-professional-discourse-with-dr-clyde-yancy</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2011/9/12/40-the-civility-of-professional-discourse-with-dr-clyde-yancy</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2011/9/12/40-the-civility-of-professional-discourse-with-dr-clyde-yancy#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="40-the-civility-of-professional-discourse-with-dr-clyde-yancy" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/40-the-civility-of-professional-discourse-with-dr-clyde-yancy.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/wZNYHIweZ68/Harrington_Show_Sept12.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2011/9/12/40-the-civility-of-professional-discourse-with-dr-clyde-yancy</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/wZNYHIweZ68/Harrington_Show_Sept12.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode40/Harrington_Show_Sept12.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#39: The uptake of clinical trial findings: Focus on OAT with Dr David Kandzari</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Recent reports indicate that the Occluded Arteries Trial (OAT)—while continuing to stir debate—has made little impact on clinical practice among US physicians. What explains this situation?&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=k-X0qD0IpEU:bmp1MQilot4:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=k-X0qD0IpEU:bmp1MQilot4:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=k-X0qD0IpEU:bmp1MQilot4:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=k-X0qD0IpEU:bmp1MQilot4:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=k-X0qD0IpEU:bmp1MQilot4:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=k-X0qD0IpEU:bmp1MQilot4:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=k-X0qD0IpEU:bmp1MQilot4:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=k-X0qD0IpEU:bmp1MQilot4:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=k-X0qD0IpEU:bmp1MQilot4:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=k-X0qD0IpEU:bmp1MQilot4:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=k-X0qD0IpEU:bmp1MQilot4:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=k-X0qD0IpEU:bmp1MQilot4:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=k-X0qD0IpEU:bmp1MQilot4:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=k-X0qD0IpEU:bmp1MQilot4:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=k-X0qD0IpEU:bmp1MQilot4:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/k-X0qD0IpEU" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Recent reports indicate that the Occluded Arteries Trial (OAT)—while continuing to stir debate—has made little impact on clinical practice among US physicians. What explains this situation? ]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p><a href="http://www.theheart.org/article/1252275.do">Recent reports</a> indicate that the <strong>Occluded Arteries Trial</strong> (OAT)&mdash;while continuing to stir debate&mdash;has made little impact on clinical practice among US physicians. What explains this situation? <strong>Dr David Kandzari</strong> joins the show to take a broad look at the design, implementation, and uptake of clinical trials, with focus on strategy bias, how to follow evidence-based medicine, and why physicians are quick to act on certain trial results (but not others).</p>
<p><strong>Dr Kandzari</strong> has served as an advisor or consultant for Medtronic, Abbott, Cordis, and Micell Technologies. He has received grants for clinical research from Abbott, Cordis, and Medtronic.</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/Harrington-COI_2010.pdf">here</a>.</p>
<p><strong>See:</strong></p>
<p><a title="UPDATED WITH COMMENTARY // Despite the results of the Occluded Artery Trial, as well as the updated 2007 clinical guidelines stating that there is no benefit to intervening late in stable acute-MI patients, physicians continue to treat these patients with" href="http://www.theheart.org/article/1252275.do">Physicians still doing late PCI of occluded arteries in stable patients </a></p>]]>
      </tho:content>
      <pubDate>Wed, 10 Aug 2011 15:25:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/k-X0qD0IpEU/39-the-uptake-of-clinical-trial-findings-focus-on-oat</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2011/8/9/39-the-uptake-of-clinical-trial-findings-focus-on-oat</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2011/8/9/39-the-uptake-of-clinical-trial-findings-focus-on-oat#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="39-the-uptake-of-clinical-trial-findings-focus-on-oat" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/39-the-uptake-of-clinical-trial-findings-focus-on-oat.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/hNQmXiTszNM/Harrington_Show_Aug9.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2011/8/9/39-the-uptake-of-clinical-trial-findings-focus-on-oat</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/hNQmXiTszNM/Harrington_Show_Aug9.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode39/Harrington_Show_Aug9.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#38: HDL cholesterol, niacin, and AIM-HIGH with Dr Jim Stein</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Is the concept of raising HDL cholesterol still pertinent in an era of well-controlled LDL levels via statin therapy? To address this question, our guest Dr Jim Stein reviews what evidence exists to indicate low HDL cholesterol may predict heart disease..&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=XC_bAlRIE9I:ZqCq8Dsc1F4:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=XC_bAlRIE9I:ZqCq8Dsc1F4:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=XC_bAlRIE9I:ZqCq8Dsc1F4:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=XC_bAlRIE9I:ZqCq8Dsc1F4:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=XC_bAlRIE9I:ZqCq8Dsc1F4:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=XC_bAlRIE9I:ZqCq8Dsc1F4:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=XC_bAlRIE9I:ZqCq8Dsc1F4:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=XC_bAlRIE9I:ZqCq8Dsc1F4:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=XC_bAlRIE9I:ZqCq8Dsc1F4:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=XC_bAlRIE9I:ZqCq8Dsc1F4:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=XC_bAlRIE9I:ZqCq8Dsc1F4:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=XC_bAlRIE9I:ZqCq8Dsc1F4:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=XC_bAlRIE9I:ZqCq8Dsc1F4:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=XC_bAlRIE9I:ZqCq8Dsc1F4:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=XC_bAlRIE9I:ZqCq8Dsc1F4:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/XC_bAlRIE9I" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Is the concept of raising HDL cholesterol still pertinent in an era of well-controlled LDL levels via statin therapy? To address this question, our guest Dr Jim Stein reviews what evidence exists to indicate low HDL cholesterol may predict heart disease..]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>Is the concept of raising HDL cholesterol still pertinent in an era of well-controlled LDL levels via statin therapy? To address this question, our guest <strong>Dr Jim Stein</strong> reviews what evidence exists to indicate low HDL cholesterol may predict heart disease, how the drug niacin fits into the equation, and what the results of the <strong>AIM-HIGH</strong> trial might mean for this hypothesis.</p>
<p>Disclosures:</p>
<p><strong>Dr Stein</strong> has served on data and safety monitoring committees (not related to niacin) for Abbott, Lilly, and Takeda. He has received royalties (not related to dyslipidemia) from the Wisconsin Alumni Research Foundation.</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/Harrington-COI_2010.pdf">here</a>.</p>
<p>See:</p>
<p><a href="http://www.theheart.org/article/1231453.do">NIH pulls plug on AIM-HIGH trial with niacin </a></p>
<p><a title="It is now a month after the surprise announcement by the US National Heart, Lung, and Blood Institute that it was stopping the AIM-HIGH trial of extended-release niacin for patients with low HDL and high triglycerides because of futility. heartwire asked several lipid experts and general cardiologists if they had changed their practice since the disappointing, albeit preliminary, results were reported. " href="http://theheart.org/article/1248191.do">What future for niacin after AIM-HIGH?</a></p>]]>
      </tho:content>
      <pubDate>Wed, 06 Jul 2011 15:05:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/XC_bAlRIE9I/38-hdl-cholesterol-niacin-and-aimhigh-with-dr-jim-stein</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2011/7/6/38-hdl-cholesterol-niacin-and-aimhigh-with-dr-jim-stein</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2011/7/6/38-hdl-cholesterol-niacin-and-aimhigh-with-dr-jim-stein#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="38-hdl-cholesterol-niacin-and-aimhigh-with-dr-jim-stein" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/38-hdl-cholesterol-niacin-and-aimhigh-with-dr-jim-stein.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>5</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/zH6VL9FjJQg/Harrington_Show_Jul6.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2011/7/6/38-hdl-cholesterol-niacin-and-aimhigh-with-dr-jim-stein</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/zH6VL9FjJQg/Harrington_Show_Jul6.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode38/Harrington_Show_Jul6.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#37: Reversible anticoagulation in RADAR with Dr Thomas Povsic</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Reversible anticoagulation may open the door to more efficacious treatment and better outcomes in settings such as PCI and valve replacement, as well as bypass surgery. But how does the risk of bleeding fit into the equation? Dr Thomas Povsic discusses.&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=pLDOJ4LU0vI:b29ee1pIZtA:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=pLDOJ4LU0vI:b29ee1pIZtA:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=pLDOJ4LU0vI:b29ee1pIZtA:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=pLDOJ4LU0vI:b29ee1pIZtA:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=pLDOJ4LU0vI:b29ee1pIZtA:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=pLDOJ4LU0vI:b29ee1pIZtA:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=pLDOJ4LU0vI:b29ee1pIZtA:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=pLDOJ4LU0vI:b29ee1pIZtA:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=pLDOJ4LU0vI:b29ee1pIZtA:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=pLDOJ4LU0vI:b29ee1pIZtA:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=pLDOJ4LU0vI:b29ee1pIZtA:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=pLDOJ4LU0vI:b29ee1pIZtA:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=pLDOJ4LU0vI:b29ee1pIZtA:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=pLDOJ4LU0vI:b29ee1pIZtA:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=pLDOJ4LU0vI:b29ee1pIZtA:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/pLDOJ4LU0vI" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Reversible anticoagulation may open the door to more efficacious treatment and better outcomes in settings such as PCI and valve replacement, as well as bypass surgery. But how does the risk of bleeding fit into the equation? Dr Thomas Povsic discusses.]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>Reversible anticoagulation may open the door to more efficacious treatment and better outcomes in settings such as PCI and valve replacement, as well as bypass surgery. But how does the risk of bleeding fit into the equation? <strong>Dr Thomas Povsic</strong> joins the show to discuss reversible anticoagulation: the clinical imperative of the <strong>RADAR</strong> trial, background on aptamer technology, and a discussion of trial results and implications for future research.</p>
<p><strong>Dr Povsic</strong> has served as an advisor or consultant for Regado Biosciences and has received grants for clinical research from Regado Biosciences and Baxter International.</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/Harrington-COI_2010.pdf">here</a>.</p>
<p>See:</p>
<p><a title="The REG1 system is said to be &quot;ideal&quot; for use in PCI, where very high levels of anticoagulation are needed for a short period. " href="http://theheart.org/article/1208729.do">RADAR: First significant clinical use of novel reversible anticoagulation system </a></p>]]>
      </tho:content>
      <pubDate>Thu, 02 Jun 2011 08:35:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/pLDOJ4LU0vI/37-reversible-anticoagulation-in-radar-with-dr-thomas-povsic</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2011/5/31/37-reversible-anticoagulation-in-radar-with-dr-thomas-povsic</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2011/5/31/37-reversible-anticoagulation-in-radar-with-dr-thomas-povsic#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="37-reversible-anticoagulation-in-radar-with-dr-thomas-povsic" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/37-reversible-anticoagulation-in-radar-with-dr-thomas-povsic.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords>acc 2011 </tho:keywords>
      <itunes:keywords>acc 2011 </itunes:keywords>
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/OYSQ9zpkXiE/Harrington_Show_June1.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2011/5/31/37-reversible-anticoagulation-in-radar-with-dr-thomas-povsic</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/OYSQ9zpkXiE/Harrington_Show_June1.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode37/Harrington_Show_June1.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#36: Antiplatelet responsiveness and personalized medicine: Lessons from GRAVITAS and TRIGGER-PCI with Dr Gregg Stone</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Antiplatelet responsiveness and personalized medicine: Lessons from GRAVITAS and TRIGGER-PCI with Dr Gregg Stone&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=Y-sUv_WAVqc:-gdmTk3JDBw:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=Y-sUv_WAVqc:-gdmTk3JDBw:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=Y-sUv_WAVqc:-gdmTk3JDBw:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=Y-sUv_WAVqc:-gdmTk3JDBw:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=Y-sUv_WAVqc:-gdmTk3JDBw:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=Y-sUv_WAVqc:-gdmTk3JDBw:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=Y-sUv_WAVqc:-gdmTk3JDBw:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=Y-sUv_WAVqc:-gdmTk3JDBw:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=Y-sUv_WAVqc:-gdmTk3JDBw:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=Y-sUv_WAVqc:-gdmTk3JDBw:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=Y-sUv_WAVqc:-gdmTk3JDBw:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=Y-sUv_WAVqc:-gdmTk3JDBw:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=Y-sUv_WAVqc:-gdmTk3JDBw:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=Y-sUv_WAVqc:-gdmTk3JDBw:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=Y-sUv_WAVqc:-gdmTk3JDBw:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/Y-sUv_WAVqc" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Antiplatelet responsiveness and personalized medicine: Lessons from GRAVITAS and TRIGGER-PCI with Dr Gregg Stone]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>The key to improved efficacy of antiplatelet regimens&mdash;in theory, at least&mdash;appears to be a personalized approach to therapy. But based on the <strong>TRIGGER-PCI</strong> and <strong>GRAVITAS </strong>trials, how productive is routine testing for platelet responsiveness in clinical practice?<strong> Dr Gregg Stone</strong> discusses his expertise in this field, why the hypothesis for TRIGGER-PCI did not work, his thoughts on the current role of genotype/phenotype testing, and why we should be optimistic about future research in this arena.</p>
<p><strong>Dr Stone</strong> has served as a consultant for Osprey, Reva, Merck, Abbott Vascular, Boston Scientific, AstraZeneca, Eli Lilly/Daiichi Sankyo, Bristol Myers-Squibb, Otsuka, Gilead, InspireMD, TherOx, the Medicines Company, Atrium, InfraReDx, Volcano, and Medtronic. He has received speaker honoraria from Vascular Solutions and holds equity in Corevalve, Ovalum, Flowcardia, Caliber, Arstasis, Micardia, Access Closure, Embrella, Guided Delivery Systems, Biostar funds, and Medfocus funds.</p>
<p>For <strong>Dr Harrington</strong>'s disclosures, click <a href="https://www.dcri.org/about-us/conflict-of-interest/Harrington-COI_2010.pdf">here</a>.</p>
<p><strong>See:</strong></p>
<p><a title="A preliminary, blinded, pooled analysis in less than one-quarter of the trial's intended enrollment indicated that the event rates were lower than expected, lower even than those of GRAVITAS." href="http://www.theheart.org/article/1200057.do">TRIGGER-PCI halted: Low events stymie platelet-reactivity trial with prasugrel, clopidogrel </a></p>
<p><a title="The authors suggest that using a more potent drug or treating to a target level of platelet aggregation may be better strategies. " href="http://www.theheart.org/article/1199049.do">GRAVITAS published: Double-dose clopidogrel ineffective for high on-treatment platelet reactivity </a></p>]]>
      </tho:content>
      <pubDate>Mon, 09 May 2011 16:25:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/Y-sUv_WAVqc/36-antiplatelet-responsiveness-and-personalized-medicine-lessons-from-gravitas-and-triggerpci-with-dr-gregg-stone</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2011/5/9/36-antiplatelet-responsiveness-and-personalized-medicine-lessons-from-gravitas-and-triggerpci-with-dr-gregg-stone</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2011/5/9/36-antiplatelet-responsiveness-and-personalized-medicine-lessons-from-gravitas-and-triggerpci-with-dr-gregg-stone#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="36-antiplatelet-responsiveness-and-personalized-medicine-lessons-from-gravitas-and-triggerpci-with-dr-gregg-stone" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/36-antiplatelet-responsiveness-and-personalized-medicine-lessons-from-gravitas-and-triggerpci-with-dr-gregg-stone.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/ss7gWTBlrvA/Harrington_Show_may09.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2011/5/9/36-antiplatelet-responsiveness-and-personalized-medicine-lessons-from-gravitas-and-triggerpci-with-dr-gregg-stone</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/ss7gWTBlrvA/Harrington_Show_may09.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode36/Harrington_Show_may09.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#35: Oral antithrombotic agents: An update for the clinical practitioner with Dr Jonathan Halperin</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>After decades of reliance on warfarin, there are finally new options for oral anticoagulation, with exciting results from the RE-LY, ROCKET, and AVERROES trials paving the way for dabigatran, rivaroxaban, and apixaban.&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=_4CgzCZ8eLA:rY_31KMGaN4:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=_4CgzCZ8eLA:rY_31KMGaN4:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=_4CgzCZ8eLA:rY_31KMGaN4:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=_4CgzCZ8eLA:rY_31KMGaN4:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=_4CgzCZ8eLA:rY_31KMGaN4:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=_4CgzCZ8eLA:rY_31KMGaN4:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=_4CgzCZ8eLA:rY_31KMGaN4:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=_4CgzCZ8eLA:rY_31KMGaN4:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=_4CgzCZ8eLA:rY_31KMGaN4:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=_4CgzCZ8eLA:rY_31KMGaN4:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=_4CgzCZ8eLA:rY_31KMGaN4:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=_4CgzCZ8eLA:rY_31KMGaN4:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=_4CgzCZ8eLA:rY_31KMGaN4:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=_4CgzCZ8eLA:rY_31KMGaN4:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=_4CgzCZ8eLA:rY_31KMGaN4:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/_4CgzCZ8eLA" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[After decades of reliance on warfarin, there are finally new options for oral anticoagulation, with exciting results from the RE-LY, ROCKET, and AVERROES trials paving the way for dabigatran, rivaroxaban, and apixaban. ]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>After decades of reliance on <strong>warfarin</strong>, there are finally new options for oral anticoagulation, with exciting results from the <strong>RE-LY</strong>, <strong>ROCKET</strong>, and <strong>AVERROES</strong> trials paving the way for <strong>dabigatran</strong>, <strong>rivaroxaban</strong>, and <strong>apixaban</strong>. With over 20 years of experience in the development of antithrombotic therapies, our guest, <strong>Dr Jonathan Halperin</strong>, discusses the road to approval of these drugs and shares practical insights for the healthcare professionals for finding their way.</p>
<p>For Dr Harrington's disclosure statement, click <a href="https://www.dcri.org/about-us/conflict-of-interest/Harrington-COI_2010.pdf">here</a>.</p>
<p>For Dr Halperin's disclosure statement, click <a href="http://www.mountsinai.org/profiles/jonathan-l-halperin">here</a>.</p>
<p>See:</p>
<p><a title="Expectedly, the new oral thrombin inhibitor received a class I recommendation as a warfarin alternative for preventing stroke/thromboembolism in patients with atrial fibrillation in a guidelines update jointly released by the AHA, ACC, and HRS. " href="http://www.theheart.org/article/1185559.do">Dabigatran joins US atrial-fib guidelines </a></p>
<p><a title="A new factor Xa inhibitor, apixaban, has cleared the penultimate hurdle on the road to EU approval for the prevention of venous thromboembolism in patients undergoing elective hip- or knee-replacement surgery." href="http://www.theheart.org/article/1200001.do">Apixaban clears EU hurdle for VTE prevention </a></p>
<p><a title="Preliminary results of the ROCKET AF study show that the new oral factor Xa inhibitor met its primary efficacy end point of noninferiority to warfarin with regard to all-cause stroke and non-CNS systemic embolism, with comparable bleeding rates. " href="http://www.theheart.org/article/1142437.do">ROCKET AF: Rivaroxaban meets primary end point </a></p>]]>
      </tho:content>
      <pubDate>Thu, 14 Apr 2011 15:15:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/_4CgzCZ8eLA/35-oral-antithrombotic-agents-an-update-for-the-clinical-practitioner-with-dr-jonathan-halperin</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2011/4/13/35-oral-antithrombotic-agents-an-update-for-the-clinical-practitioner-with-dr-jonathan-halperin</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2011/4/13/35-oral-antithrombotic-agents-an-update-for-the-clinical-practitioner-with-dr-jonathan-halperin#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="35-oral-antithrombotic-agents-an-update-for-the-clinical-practitioner-with-dr-jonathan-halperin" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/35-oral-antithrombotic-agents-an-update-for-the-clinical-practitioner-with-dr-jonathan-halperin.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/60OuC2bEWic/Harrington_Show_Apr14.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2011/4/13/35-oral-antithrombotic-agents-an-update-for-the-clinical-practitioner-with-dr-jonathan-halperin</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/60OuC2bEWic/Harrington_Show_Apr14.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode35/Harrington_Show_Apr14.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#34: Healthcare reform update: Clinical and business implications for cardiologists </title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Where does healthcare reform stand, and what are the implications for cardiologists? Physician and business leader Dr Kevin Schulman joins the show to help clarify the healthcare debate and shine light on how the new Congress ...&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gWWN_Krl3PM:nHEcHVXaNHY:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gWWN_Krl3PM:nHEcHVXaNHY:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gWWN_Krl3PM:nHEcHVXaNHY:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gWWN_Krl3PM:nHEcHVXaNHY:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=gWWN_Krl3PM:nHEcHVXaNHY:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gWWN_Krl3PM:nHEcHVXaNHY:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gWWN_Krl3PM:nHEcHVXaNHY:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=gWWN_Krl3PM:nHEcHVXaNHY:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gWWN_Krl3PM:nHEcHVXaNHY:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gWWN_Krl3PM:nHEcHVXaNHY:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=gWWN_Krl3PM:nHEcHVXaNHY:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gWWN_Krl3PM:nHEcHVXaNHY:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gWWN_Krl3PM:nHEcHVXaNHY:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=gWWN_Krl3PM:nHEcHVXaNHY:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gWWN_Krl3PM:nHEcHVXaNHY:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/gWWN_Krl3PM" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Where does healthcare reform stand, and what are the implications for cardiologists? Physician and business leader Dr Kevin Schulman joins the show to help clarify the healthcare debate and shine light on how the new Congress ...]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>Where does healthcare reform stand, and what are the implications for cardiologists? Physician and business leader <strong>Dr Kevin Schulman</strong> joins the show to help clarify the healthcare debate and shine light on how the new Congress and future presidential elections influence reform. How does the deficit shape the debate? What are the implications for the current reimbursement system and private practice partnerships with hospitals? Are there any grounds for optimism?</p>
<p><strong>See:</strong></p>
<p><strong></strong>Richman BD, Schulman KA. A cautious path forward on accountable care organizations. JAMA. 2011 Feb 9;305(6):602-3. Available <a href="http://jama.ama-assn.org/content/305/6/602.extract">here</a>.</p>
<p><a title="By reducing malpractice-insurance premiums and defensive medicine, the bill would trim federal healthcare spending, says the Congressional Budget Office. It would also lower health-insurance premiums for employers. " href="http://www.theheart.org/article/1198007.do">Tort-reform bill would cut deficit by $40 billion </a></p>
<p><a title="The president's plan would delay a massive cut in Medicare pay to physicians until January 1, 2014 and instead freeze reimbursement rates at current levels. " href="http://www.theheart.org/article/1185051.do">Obama's new budget proposes two-year "doc fix" </a></p>
<p><a title="The proposed legislation calls for capping noneconomic damages in malpractice cases at $250&nbsp;000, a measure long supported by organized medicine but opposed by Congressional Democrats." href="http://www.theheart.org/article/1178699.do">Tough tort-reform bill faces challenges </a></p>
<p><a title="UPDATED WITH COMMENTARY // The Obama administration has suddenly withdrawn a regulation that made end-of-living counseling a reimbursable component of Medicare annual wellness visits. It had taken effect January 1. " href="http://www.theheart.org/article/1169007.do">Reimbursement reversal for "advanced care" talk </a></p>
<p><a title="The bill averts a 25% Medicare pay cut for physicians set for New Year's Day and freezes rates through the end of 2011." href="http://www.theheart.org/article/1161621.do">One-year Medicare doc fix clears Congress, goes to President Obama </a></p>
<p><a href="../../2010/4/26/episode-22-business-and-practice-implications-of-healthcare-reform-with-physician-and">Episode #22: Business and practice implications of healthcare reform with physician and business school leader Dr Kevin Schulman </a></p>]]>
      </tho:content>
      <pubDate>Wed, 30 Mar 2011 14:50:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/gWWN_Krl3PM/34-healthcare-reform-update-clinical-and-business-implications-for-cardiologists</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2011/3/30/34-healthcare-reform-update-clinical-and-business-implications-for-cardiologists</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2011/3/30/34-healthcare-reform-update-clinical-and-business-implications-for-cardiologists#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="34-healthcare-reform-update-clinical-and-business-implications-for-cardiologists" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/34-healthcare-reform-update-clinical-and-business-implications-for-cardiologists.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/4tJFMPbaCo4/Harrington_Show_Mar29.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2011/3/30/34-healthcare-reform-update-clinical-and-business-implications-for-cardiologists</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/4tJFMPbaCo4/Harrington_Show_Mar29.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode34/Harrington_Show_Mar29.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#33: Quality assurance in cardiology with Dr John Rumsfeld</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Quality assurance—or appropriate use of cardiology procedures—is a hot topic that defies simple quantification and has important ramifications for patients, healthcare professionals, and society at-large. Join Dr John Rumsfeld.&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gRyw2EuXw70:RpsLPafDQ_8:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gRyw2EuXw70:RpsLPafDQ_8:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gRyw2EuXw70:RpsLPafDQ_8:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gRyw2EuXw70:RpsLPafDQ_8:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=gRyw2EuXw70:RpsLPafDQ_8:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gRyw2EuXw70:RpsLPafDQ_8:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gRyw2EuXw70:RpsLPafDQ_8:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=gRyw2EuXw70:RpsLPafDQ_8:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gRyw2EuXw70:RpsLPafDQ_8:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gRyw2EuXw70:RpsLPafDQ_8:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=gRyw2EuXw70:RpsLPafDQ_8:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gRyw2EuXw70:RpsLPafDQ_8:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gRyw2EuXw70:RpsLPafDQ_8:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=gRyw2EuXw70:RpsLPafDQ_8:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=gRyw2EuXw70:RpsLPafDQ_8:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/gRyw2EuXw70" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Quality assurance—or appropriate use of cardiology procedures—is a hot topic that defies simple quantification and has important ramifications for patients, healthcare professionals, and society at-large. Join Dr John Rumsfeld.]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>Quality assurance&mdash;or appropriate use of cardiology procedures&mdash;is a hot topic that defies simple quantification and has important ramifications for patients, healthcare professionals, and society at-large. <strong>Dr John Rumsfeld</strong> joins the show to share his thoughts on QA&mdash;how to measure it, who should assume responsibility for the process, the role of professional societies, and how reliable feedback can affect quality.</p>
<p>See:</p>
<ul>
<li><a title="CORRECTED // The perils of coronary computed tomographic angiography are highlighted in the latest installment of the  &quot;Less is More&quot; series in the Archives of Internal Medicine, in which a 52-year-old woman presenting with chest pain, but no other sympto" href="http://www.theheart.org/article/1164425.do">Case study shows how "just-in-case" CCTA in a low-risk patient may spectacularly backfire </a></li>
<li><a title="A collaboration of several professional societies, the new appropriate-use criteria for cardiac computed tomography are intended to be a &quot;practical guide&quot; for patients and doctors on the application of cardiac CT for a wide variety of indications. " href="http://www.theheart.org/article/1140843.do">Cardiac computed tomography appropriateness criteria cover 93 clinical situations </a></li>
<li><a title="No word yet from the Maryland Medical Board as to whether it will be taking action against former St Joseph's department of cardiology chair Dr Mark Midei, accused of performing unnecessary stenting procedures, after a private meeting with him August 4, 2" href="http://www.theheart.org/article/1117469.do">Maryland mulls Midei case as cardiology orgs ask legislators to leave policing procedures to doctors <br /></a></li>
</ul>]]>
      </tho:content>
      <pubDate>Thu, 10 Feb 2011 16:25:00 -0500</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/gRyw2EuXw70/33-quality-assurance-in-cardiology-with-dr-john-rumsfeld</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2011/2/10/33-quality-assurance-in-cardiology-with-dr-john-rumsfeld</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2011/2/10/33-quality-assurance-in-cardiology-with-dr-john-rumsfeld#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="33-quality-assurance-in-cardiology-with-dr-john-rumsfeld" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/33-quality-assurance-in-cardiology-with-dr-john-rumsfeld.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/b0-h6hVm_m8/1176241.do" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2011/2/10/33-quality-assurance-in-cardiology-with-dr-john-rumsfeld</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/b0-h6hVm_m8/1176241.do" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://www.theheart.org/article/1176241.do </feedburner:origEnclosureLink></item>
    <item>
      <title>#32: Advances in heart-failure research with Dr Clyde Yancy</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Advances in heart-failure research with Dr Clyde Yancy. Heart-failure is estimated to account for two million hospital admissions per year in the US, based on primary and secondary diagnosis.&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=r2zBY9PESBQ:wOqfB7ydfjc:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=r2zBY9PESBQ:wOqfB7ydfjc:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=r2zBY9PESBQ:wOqfB7ydfjc:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=r2zBY9PESBQ:wOqfB7ydfjc:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=r2zBY9PESBQ:wOqfB7ydfjc:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=r2zBY9PESBQ:wOqfB7ydfjc:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=r2zBY9PESBQ:wOqfB7ydfjc:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=r2zBY9PESBQ:wOqfB7ydfjc:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=r2zBY9PESBQ:wOqfB7ydfjc:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=r2zBY9PESBQ:wOqfB7ydfjc:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=r2zBY9PESBQ:wOqfB7ydfjc:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=r2zBY9PESBQ:wOqfB7ydfjc:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=r2zBY9PESBQ:wOqfB7ydfjc:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=r2zBY9PESBQ:wOqfB7ydfjc:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=r2zBY9PESBQ:wOqfB7ydfjc:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/r2zBY9PESBQ" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Advances in heart-failure research with Dr Clyde Yancy. Heart-failure is estimated to account for two million hospital admissions per year in the US, based on primary and secondary diagnosis. ]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[<p>Heart-failure is estimated to account for two million hospital admissions per year in the US, based on primary and secondary diagnosis. Despite the amplitude of this burden, there is reason for cautious optimism, with encouraging results from clinical trials in 2010 that point to better treatment options and outcomes. In this comprehensive review, <strong>Dr Clyde Yancy</strong> discusses important recent research and how trials such as <strong>RAFT</strong>, <strong>EMPHASIS-HF</strong>, <strong>ASCEND-HF</strong>, and <strong>ADVANCE</strong> will help ambulatory, decompensated, and advance heart-failure patients.</p>
<p>&nbsp;</p>
<p>See:</p>
<ul>
<li><a href="http://www.theheart.org/editorial-program/1143471.do">ROCKET AF, EMPHASIS-HF, and DEFINE: AHA 2010 Overview from Chicago </a></li>
<li><a title="The trial shows that cardiac resynchronization therapy provides a survival benefit over ICD alone in patients with NYHA class 2 or 3 heart failure, a wide QRS duration, and left ventricular systolic dysfunction." href="http://www.theheart.org/article/1147233.do">CRT is a lifeRAFT for class 2 and 3 HF patients with low EF and wide QRS </a></li>
<li><a title="UPDATED WITH COMMENTARY // The aldosterone antagonist produced large reductions in both the risk of death and the risk of hospitalization compared with placebo in patients with systolic heart failure and mild symptoms." href="http://www.theheart.org/article/1147165.do">EMPHASIS-HF: Eplerenone shows large benefits in milder heart failure </a></li>
<li><a title="Five years ago, one of the biggest, most burning questions in cardiology was whether the once-popular IV vasodilator hurt or helped in acute decompensated heart failure. The trial designed to settle the issue now says no to the first and yes, but only a l" href="http://www.theheart.org/article/1147999.do">ASCEND-HF: Nesiritide safe but of limited dyspnea benefit in acute HF </a></li>
<li><a title="The ADVANCE study, looking at the use of a new, smaller, left ventricular assist device as a bridge to transplant, has shown that it is noninferior to the currently available LVAD, the HeartMate II. Although long-term data are needed, these early results " href="http://www.theheart.org/article/1147661.do">ADVANCE: New LVAD equivalent to HeartMate II, nonrandomized study shows&nbsp;</a></li>
</ul>]]>
      </tho:content>
      <pubDate>Mon, 10 Jan 2011 16:05:00 -0500</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/r2zBY9PESBQ/32-advances-in-heartfailure-research-with-dr-clyde-yancy</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2010/12/17/32-advances-in-heartfailure-research-with-dr-clyde-yancy</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2010/12/17/32-advances-in-heartfailure-research-with-dr-clyde-yancy#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="32-advances-in-heartfailure-research-with-dr-clyde-yancy" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/32-advances-in-heartfailure-research-with-dr-clyde-yancy.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords>AHA 2010 </tho:keywords>
      <itunes:keywords>AHA 2010 </itunes:keywords>
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/I1FAw_Zj48E/Harrington_Show_Dec15.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2010/12/17/32-advances-in-heartfailure-research-with-dr-clyde-yancy</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/I1FAw_Zj48E/Harrington_Show_Dec15.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode32/Harrington_Show_Dec15.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#31: Atkins, diet, obesity, and cardiovascular disease risk with Dr Eric Westman</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Atkins, diet, obesity, and cardiovascular disease risk with Dr Eric Westman. Hotly debated among healthcare professionals, "low-carb" diets—such as Atkins—have soared in popularity, offering easy-to-follow approaches and rapid results. But are they safe?&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8DyxG2y_nn0:_QA2SOQqWIU:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8DyxG2y_nn0:_QA2SOQqWIU:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8DyxG2y_nn0:_QA2SOQqWIU:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8DyxG2y_nn0:_QA2SOQqWIU:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=8DyxG2y_nn0:_QA2SOQqWIU:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8DyxG2y_nn0:_QA2SOQqWIU:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8DyxG2y_nn0:_QA2SOQqWIU:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=8DyxG2y_nn0:_QA2SOQqWIU:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8DyxG2y_nn0:_QA2SOQqWIU:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8DyxG2y_nn0:_QA2SOQqWIU:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=8DyxG2y_nn0:_QA2SOQqWIU:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8DyxG2y_nn0:_QA2SOQqWIU:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8DyxG2y_nn0:_QA2SOQqWIU:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=8DyxG2y_nn0:_QA2SOQqWIU:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=8DyxG2y_nn0:_QA2SOQqWIU:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/8DyxG2y_nn0" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Atkins, diet, obesity, and cardiovascular disease risk with Dr Eric Westman. Hotly debated among healthcare professionals, "low-carb" diets—such as Atkins—have soared in popularity, offering easy-to-follow approaches and rapid results. But are they safe?]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[  <p>Hotly debated among healthcare professionals, &quot;low-carb&quot; diets&mdash;such as Atkins&mdash;have soared in popularity, offering easy-to-follow approaches and rapid results. But are they safe? <strong>Dr Eric Westman</strong> joins the show to discuss safety, his research in lifestyle intervention, and thoughts on how curbing the intake of carbohydrates can help tackle the obesity pandemic.</p>    <p><span>See:</span></p>  <p><a href="http://www.theheart.org/article/1137677.do" title="The Atkins diet is always the subject of controversy when it comes to scientific claims. The latest assertion by one proponent is that it can help treat diabetes, mostly because people can lose weight easily while on this diet. But others argue that there"><span><span>Kill or cure? Atkins diet debated in diabetes </span></span></a></p>  <p><span><span>Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. </span></span><a href="http://www.ncbi.nlm.nih.gov/pubmed/20071648"><span><span>Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease.</span></span></a><span><span> <span><em>Am J Clin Nutr</em></span><span>. 2010 Mar;91(3):535-46. </span></span></span><a href="http://www.ncbi.nlm.nih.gov/pubmed/20071648"><span><span>Abstract</span></span></a><span><span><span>.</span></span></span></p>    <p>Shai I, Spence JD, Schwarzfuchs D, et al. Dietary intervention to reverse carotid atherosclerosis. <span><em>Circulation</em></span><span>. 2010 Mar 16;121(10):1200-8. </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/20194883">Abstract</a><span>.</span></p>  ]]>
      </tho:content>
      <pubDate>Fri, 17 Dec 2010 10:20:00 -0500</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/8DyxG2y_nn0/31-atkins-diet-obesity-and-cardiovascular-disease-risk-with-dr-eric-westman</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2010/12/10/31-atkins-diet-obesity-and-cardiovascular-disease-risk-with-dr-eric-westman</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2010/12/10/31-atkins-diet-obesity-and-cardiovascular-disease-risk-with-dr-eric-westman#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="31-atkins-diet-obesity-and-cardiovascular-disease-risk-with-dr-eric-westman" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/31-atkins-diet-obesity-and-cardiovascular-disease-risk-with-dr-eric-westman.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>8</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/c3gpattknZY/Bob_Harrington_Show_Dec10.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2010/12/10/31-atkins-diet-obesity-and-cardiovascular-disease-risk-with-dr-eric-westman</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/c3gpattknZY/Bob_Harrington_Show_Dec10.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode31/Bob_Harrington_Show_Dec10.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#30: Canadian antiplatelet guidelines with Dr Alan Bell</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>Notable for their therapy-based approach, rigor, and clarity, the Canadian Cardiovascular Society (CCS) antiplatelet guidelines were recently presented by coauthors Drs Alan Bell and Jean-François Tanguay at the CCS annual meeting in Montreal.&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=vFBDzBGFth4:HDMJXBaqCvQ:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=vFBDzBGFth4:HDMJXBaqCvQ:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=vFBDzBGFth4:HDMJXBaqCvQ:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=vFBDzBGFth4:HDMJXBaqCvQ:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=vFBDzBGFth4:HDMJXBaqCvQ:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=vFBDzBGFth4:HDMJXBaqCvQ:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=vFBDzBGFth4:HDMJXBaqCvQ:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=vFBDzBGFth4:HDMJXBaqCvQ:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=vFBDzBGFth4:HDMJXBaqCvQ:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=vFBDzBGFth4:HDMJXBaqCvQ:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=vFBDzBGFth4:HDMJXBaqCvQ:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=vFBDzBGFth4:HDMJXBaqCvQ:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=vFBDzBGFth4:HDMJXBaqCvQ:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=vFBDzBGFth4:HDMJXBaqCvQ:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=vFBDzBGFth4:HDMJXBaqCvQ:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/vFBDzBGFth4" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[Notable for their therapy-based approach, rigor, and clarity, the Canadian Cardiovascular Society (CCS) antiplatelet guidelines were recently presented by coauthors Drs Alan Bell and Jean-François Tanguay at the CCS annual meeting in Montreal.]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[      <p>Notable for their therapy-based approach, rigor, and clarity, the <strong>Canadian Cardiovascular Society</strong><span> (CCS) antiplatelet guidelines were recently </span><a href="http://www.theheart.org/article/1142157.do"><span>presented</span></a><span> by coauthors <strong>Drs Alan Bell</strong> and <strong>Jean-Fran&ccedil;ois Tanguay</strong> at the CCS annual meeting in Montreal. Dr Bell joins the show to discuss the raison d&rsquo;&ecirc;tre, methodology, and aspirations of the new guidelines, while addressing specific line items, including aspirin dosing, duration of dual antiplatelet therapy poststenting, primary prevention, and interaction with proton-pump inhibitors.</span></p><p><span><span>See:</span></span></p>    <p><a href="http://www.theheart.org/article/1142157.do" title="The new guidelines include recommendations on dual antiplatelet therapy duration and the role of prasugrel and COX 2 inhibitors and, for the first time, recommend against the routine use of aspirin for primary prevention.">First of their kind: Canadian guidelines specific to antiplatelet therapy </a></p>  <p><a href="http://www.theheart.org/documents/sitestructure/en/resources/PDF/antiplatelettherapyrecommendations.pdf"><span>Canadian Cardiovascular Society Antiplatelet Guideline 2010</span></a></p>  ]]>
      </tho:content>
      <pubDate>Fri, 03 Dec 2010 11:35:00 -0500</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/vFBDzBGFth4/30-canadian-antiplatelet-guidelines-with-dr-alan-bell</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2010/12/2/30-canadian-antiplatelet-guidelines-with-dr-alan-bell</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2010/12/2/30-canadian-antiplatelet-guidelines-with-dr-alan-bell#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="30-canadian-antiplatelet-guidelines-with-dr-alan-bell" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/30-canadian-antiplatelet-guidelines-with-dr-alan-bell.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/UX1TqVA4Vzw/Bob_Harrington_Show_Dec1.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2010/12/2/30-canadian-antiplatelet-guidelines-with-dr-alan-bell</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/UX1TqVA4Vzw/Bob_Harrington_Show_Dec1.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode30/Bob_Harrington_Show_Dec1.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#29: Obesity in America with Dr Thad Waites </title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>According to the Center of Disease Control, 72.5 million Americans are obese (with a body-mass index [BMI] &gt;30), and 27% of the increase in healthcare costs is related to the treatment of obesity. Dr Thad Waites joins the show to discuss.&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=jVr1JxXfiiA:MWVGjuFgSek:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=jVr1JxXfiiA:MWVGjuFgSek:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=jVr1JxXfiiA:MWVGjuFgSek:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=jVr1JxXfiiA:MWVGjuFgSek:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=jVr1JxXfiiA:MWVGjuFgSek:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=jVr1JxXfiiA:MWVGjuFgSek:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=jVr1JxXfiiA:MWVGjuFgSek:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=jVr1JxXfiiA:MWVGjuFgSek:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=jVr1JxXfiiA:MWVGjuFgSek:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=jVr1JxXfiiA:MWVGjuFgSek:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=jVr1JxXfiiA:MWVGjuFgSek:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=jVr1JxXfiiA:MWVGjuFgSek:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=jVr1JxXfiiA:MWVGjuFgSek:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=jVr1JxXfiiA:MWVGjuFgSek:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=jVr1JxXfiiA:MWVGjuFgSek:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/jVr1JxXfiiA" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[According to the Center of Disease Control, 72.5 million Americans are obese (with a body-mass index [BMI] >30), and 27% of the increase in healthcare costs is related to the treatment of obesity. Dr Thad Waites joins the show to discuss.]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[  <p>According to the <a href="http://www.cdc.gov/obesity/data/trends.html">Center of Disease Control</a>, 72.5 million Americans are obese (with a body-mass index [BMI] &gt;30), and 27% of the increase in healthcare costs is related to the treatment of obesity. <strong>Dr Thad Waites</strong> joins the show to discuss these sobering statistics, the cardiovascular implications of obesity, what we can do to reverse the pandemic and the implications of the controversial obesity paradox in outcomes for CV disease.</p>    <p><span>Are you witnessing the obesity pandemic in your cardiovascular practice?</span></p>    <p><span><span>See:</span></span></p>    <p><a href="http://www.cdc.gov/obesity/data/trends.html">Center for Disease Control. US Obesity Trends</a></p>  <p><a href="http://www.theheart.org/article/1138263.do" title="Obesity experts say physicians and drug regulators need to sit up and take notice: the pharmacy shelves are all but bare of weight-loss drugs. Some say soaring BMIs mean certain risks should be deemed acceptable&amp;#151;even in &quot;healthy&quot; obese subjects&amp;#151;">Diet drug dilemma: If CVD drops tomorrow are risks justified today? </a></p>  <p><a href="http://www.theheart.org/article/1137677.do" title="The Atkins diet is always the subject of controversy when it comes to scientific claims. The latest assertion by one proponent is that it can help treat diabetes, mostly because people can lose weight easily while on this diet. But others argue that there">Kill or cure? Atkins diet debated in diabetes </a></p>  ]]>
      </tho:content>
      <pubDate>Mon, 01 Nov 2010 11:05:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/jVr1JxXfiiA/episode-29-obesity-in-america-with-dr-thad-waites</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2010/11/1/episode-29-obesity-in-america-with-dr-thad-waites</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2010/11/1/episode-29-obesity-in-america-with-dr-thad-waites#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="episode-29-obesity-in-america-with-dr-thad-waites" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/episode-29-obesity-in-america-with-dr-thad-waites.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords />
      <itunes:keywords />
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/RmGhFwxjZ9g/Bob_Harrington_Show_oct29.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2010/11/1/episode-29-obesity-in-america-with-dr-thad-waites</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/RmGhFwxjZ9g/Bob_Harrington_Show_oct29.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode29/Bob_Harrington_Show_oct29.mp3</feedburner:origEnclosureLink></item>
    <item>
      <title>#28: AVERROES:  Apixaban as a future alternative to warfarin with Dr Stuart Connolly</title>
      <category>The Bob Harrington Show</category>
      <author>info@theheart.org</author>
      <description>The findings of the AVERROES trial foretell a future with appropriate treatment for patients with atrial fibrillation who are not candidates for anticoagulation with oral vitamin-K antagonists.&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=CpT7mgfYzVA:pF0TiY0EBGA:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=CpT7mgfYzVA:pF0TiY0EBGA:63t7Ie-LG7Y"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=63t7Ie-LG7Y" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=CpT7mgfYzVA:pF0TiY0EBGA:dnMXMwOfBR0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=dnMXMwOfBR0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=CpT7mgfYzVA:pF0TiY0EBGA:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=CpT7mgfYzVA:pF0TiY0EBGA:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=CpT7mgfYzVA:pF0TiY0EBGA:7Q72WNTAKBA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=7Q72WNTAKBA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=CpT7mgfYzVA:pF0TiY0EBGA:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=CpT7mgfYzVA:pF0TiY0EBGA:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=CpT7mgfYzVA:pF0TiY0EBGA:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=qj6IDK7rITs" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=CpT7mgfYzVA:pF0TiY0EBGA:KwTdNBX3Jqk"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=CpT7mgfYzVA:pF0TiY0EBGA:KwTdNBX3Jqk" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=CpT7mgfYzVA:pF0TiY0EBGA:l6gmwiTKsz0"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=l6gmwiTKsz0" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=CpT7mgfYzVA:pF0TiY0EBGA:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?i=CpT7mgfYzVA:pF0TiY0EBGA:gIN9vFwOqvQ" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/bob-harrington-show?a=CpT7mgfYzVA:pF0TiY0EBGA:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/bob-harrington-show?d=TzevzKxY174" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/bob-harrington-show/~4/CpT7mgfYzVA" height="1" width="1"/&gt;</description>
      <itunes:summary>
        <![CDATA[The findings of the AVERROES trial foretell a future with appropriate treatment for patients with atrial fibrillation who are not candidates for anticoagulation with oral vitamin-K antagonists. ]]>
      </itunes:summary>
      <tho:content>
        <![CDATA[  <p>The findings of the <strong>AVERROES</strong> trial foretell a future with appropriate treatment for patients with atrial fibrillation who are not candidates for anticoagulation with oral vitamin-K antagonists. In this discussion, <strong>Dr Stuart Connolly</strong> describes the design and findings of this important trial, the safety and efficacy data for <strong>apixaban</strong>, and shares his predictions for better anticoagulation options for this patient set.</p>    <p>What are your thoughts on apixaban as a future alternative to warfarin?</p>    <p><span><span>See:</span></span></p>    <p><a href="http://www.theheart.org/article/1116449.do" title="Atrial-fibrillation patients in the trial treated with apixaban had a 54% lower risk of stroke or systemic embolic events, and, of note, the reduction came without an increase in bleeding events. The positive results now leave clinicians awaiting head-to-">AVERROES: Apixaban yields significant reductions in stroke, no increased bleeding </a></p>  <p><a href="http://www.theheart.org/editorial-program/1107779.do">AVERROES, SHIFT, and the Alpha Omega Trial: The Stockholm Survey from ESC 2010 </a></p>  <p><a href="http://www.theheart.org/podcast/video/trials-and-pis-with-dr-michael-gibson/averroes-with-dr-stuart-j-connolly.do"><span>AVERROES with Dr Stuart J Connolly</span></a></p>  <p><a href="http://www.theheart.org/editorial-program/1119685.do">ESC 2010 research highlights: A slideshow presentation </a></p>  ]]>
      </tho:content>
      <pubDate>Thu, 07 Oct 2010 16:15:00 -0400</pubDate>
      <link>http://feedproxy.google.com/~r/bob-harrington-show/~3/CpT7mgfYzVA/episode-28-averroes--apixaban-as-a-future-alternative-to-warfarin-with-dr-stuart-connolly</link>
      <guid isPermaLink="false">http://radio.theheart.org/bob-harrington-show/2010/10/7/episode-28-averroes--apixaban-as-a-future-alternative-to-warfarin-with-dr-stuart-connolly</guid>
      <comments>http://radio.theheart.org/bob-harrington-show/2010/10/7/episode-28-averroes--apixaban-as-a-future-alternative-to-warfarin-with-dr-stuart-connolly#comments</comments>
      
      <tho:blogInfo blogPath="bob-harrington-show" community="radio" language="English" postPath="episode-28-averroes--apixaban-as-a-future-alternative-to-warfarin-with-dr-stuart-connolly" />
      <itunes:image href="http://radio.theheart.org/images/bob-harrington-show/rss_banner_url.jpg" />
      <tho:imageSmall>
        <tho:name>The Bob Harrington Show</tho:name>
        <tho:url>http://radio.theheart.org/images/thumbnails/episode-28-averroes--apixaban-as-a-future-alternative-to-warfarin-with-dr-stuart-connolly.jpg</tho:url>
      </tho:imageSmall>
      <tho:itunes>http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?i=44906298&amp;id=295997850</tho:itunes>
      <tho:commentCount>0</tho:commentCount>
      <tho:keywords>ESC 2010 </tho:keywords>
      <itunes:keywords>ESC 2010 </itunes:keywords>
    <media:content url="http://feedproxy.google.com/~r/bob-harrington-show/~5/pUD-TFKNMYM/Bob_Harrington_Show_oct5.mp3" type="audio/mp3" /><itunes:subtitle>Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</itunes:subtitle><itunes:author>info@theheart.org</itunes:author><feedburner:origLink>http://radio.theheart.org/bob-harrington-show/2010/10/7/episode-28-averroes--apixaban-as-a-future-alternative-to-warfarin-with-dr-stuart-connolly</feedburner:origLink><enclosure url="http://feedproxy.google.com/~r/bob-harrington-show/~5/pUD-TFKNMYM/Bob_Harrington_Show_oct5.mp3" length="0" type="audio/mp3" /><feedburner:origEnclosureLink>http://media.theheart.org/podcasts/harrington/media/Episode28/Bob_Harrington_Show_oct5.mp3</feedburner:origEnclosureLink></item>
  <media:credit role="author">theheart.org</media:credit><media:rating>nonadult</media:rating><media:description type="plain">Cardiologist, Dr Bob Harrington, from Duke Clinical Research Institute interviews cardiology leaders on the latest cardiology trials, trends, and conferences.</media:description></channel>
</rss>

